Overweight/ObesityCRANOSNCT07460856
Effects of Cranberry on Gut and Metabolic Health
A study testing Cranberry beverage in people with Overweight/Obesity and Metabolic Syndrome, run by Laval University at 1 site in Canada.
Trial summary
The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Read more about this study
- Who is it for?
- Ages 25 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Overweight/Obesity, Metabolic Syndrome, Insulin Resistance
- What is being tested?
- Cranberry beverage
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 73 participants
- Where
- 1 siteCanada
- Study dates
- 7 Jul 2025to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- body mass index between 25 and 40 kg/m2
- at least one of the following criteria: fasting plasma insulin >60 pmol/L, fasting glycemia between 5.5 and 6.9 mmol/L, glycated hemoglobin (HbA1c) level of 5.7- 6.4% and/or fasting triglyceride >1.35 mmol/L.
Who cannot join
- to have aversion to cranberry products
- regularly drinking alcohol (>2 glasses/day)
- having a significant change in body weight in the past 3 months (±5% of their body weight) due to bariatric surgery or other conditions
- taking medication which may affect the study outcomes (i.e. antidiabetic and/or cholesterol or lipid-lowering medications and/or glucocorticosteroid in supraphysiological doses and/or anti-obesity medications)
- taking regular probiotics and prebiotics (including fruit/berry polyphenol supplements) in the past 3 months
- having eating disorders
Show all 9Show fewer
- had undergone major surgery 3 months prior to the study or if they had one planned
- if they had intestinal malabsorption, cirrhosis or chronic kidney disease
- being pregnant, planning a pregnancy, or breastfeeding.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
INAF, Université Laval
Québec, Quebec, G1V0A6
Julie Marois, M.Sc., 1-418-656-5258, julie.marois@fsaa.ulaval.ca
About this study
The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.
The primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.
This randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.
- Conditions
- Overweight/Obesity, Metabolic Syndrome, Insulin Resistance, Microbiota
- Being tested
- Cranberry beverage, Placebo beverage
- Medical subject headings
- Overweight, Obesity, Metabolic Syndrome, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cranberry beverageDietary supplement
Daily consumption of 240 ml of cranberry beverage for 12 weeks.
Placebo beverageDietary supplement
Daily consumption of 240 ml of placebo beverage for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Cranberry beverage | Experimental | Not described Receives: Dietary Supplement: Cranberry beverage |
| Placebo beverage | Placebo comparator | Not described Receives: Dietary Supplement: Placebo beverage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in glucose homeostasis
Assessment of glucose concentrations during a 3-hour oral glucose tolerance test (OGTT)
Measured: Pre and post each treatment (12 week/each)
Change in insulin secretion
Assessment of insulin a concentrations during a 3-hour oral glucose tolerance test (OGTT)
Measured: Pre and post each treatment (12 week/each)
Change in insulin secretion
Assessment of C-Peptide concentrations during a 3-hour oral glucose tolerance test (OGTT)
Measured: Pre and post each treatment (12 week/each)
Change in lipid profile
Assessment of triglycerides, LDL-cholesterol and HDL-cholesterol
Measured: Pre and post each treatment (12 week/each)
Secondary outcomes (9)
Change in other measures of glucose homeostasis
Assessment of glycated hemoglobin (HbA1c)
Measured: Pre and post each treatment (12 week/each)
Change in blood pressure
Assessment of systolic and diastolic blood pressure
Measured: Pre and post each treatment (12 week/each)
Change in chronic inflammation
Assessment of plasma high sensitive C-Reactive Protein (hs-CRP) concentrations
Measured: Pre and post each treatment (12 week/each)
Change in anthropometric measurements
Assessment of body mass index (BMI) using weight and height. These two measurements will be combined to calculate BMI in kg/m2
Measured: Pre and post each treatment (12 week/each)
Change in anthropometric measurements
Assessment of waist circumference
Measured: Pre and post each treatment (12 week/each)
Change in body composition
Assessment of changes in lean mass, fat mass and visceral fat mass (all in grams) using body composition by Dual X-ray Absorptiometry scan
Measured: Pre and post each treatment (12 week/each)
Change in gut microbiota
Assessment of global variation of the fecal microbiota
Measured: Pre and post each treatment (12 week/each)
Change in gut microbiota function
Assessment of short-chain fatty acid (SCFA) in feces
Measured: Pre and post each treatment (12 week/each)
Change in fat accumulation in the liver
Evaluation of fat accumulation using magnetic resonance imaging (MRI) in a subgroup of women only.
Measured: Pre and post each treatment (12 week/each)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2026
- Study start7 Jul 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight/ObesityStudies of the same condition, open and under way.
- More trials run by Laval UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 73 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Laval University
- Sponsor type
- University, hospital or other
- Collaborators
- Ocean Spray Cranberries, Inc.
- Responsible party
- Principal investigator, André Marette, Laval University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07460856
- Sponsor's protocol ID
- CRANOS 2024-530
- Acronym
- CRANOS
- Status last verified
- Mar 2026
- First submitted
- 28 Jan 2026
- Last updated
- 10 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Cranberry on Gut and Metabolic Health
- ClinicalTrials.gov ID
- NCT07460856
- Acronym / sponsor ID
- CRANOS / CRANOS 2024-530
- Conditions
- Overweight/Obesity, Metabolic Syndrome, Insulin Resistance, Microbiota
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 73 participants (estimated)
- Lead sponsor
- Laval UniversityUniversity, hospital or other
- Collaborators
- Ocean Spray Cranberries, Inc.
- Study start
- 7 Jul 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 10 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.
The primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.
This randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cranberry beverage | Experimental | Dietary Supplement: Cranberry beverage |
| Placebo beverage | Placebo comparator | Dietary Supplement: Placebo beverage |
Who may qualify
- Ages
- 25 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- body mass index between 25 and 40 kg/m2
- at least one of the following criteria: fasting plasma insulin >60 pmol/L, fasting glycemia between 5.5 and 6.9 mmol/L, glycated hemoglobin (HbA1c) level of 5.7- 6.4% and/or fasting triglyceride >1.35 mmol/L.
Key exclusion criteria (9 listed)
- to have aversion to cranberry products
- regularly drinking alcohol (>2 glasses/day)
- having a significant change in body weight in the past 3 months (±5% of their body weight) due to bariatric surgery or other conditions
- taking medication which may affect the study outcomes (i.e. antidiabetic and/or cholesterol or lipid-lowering medications and/or glucocorticosteroid in supraphysiological doses and/or anti-obesity medications)
- taking regular probiotics and prebiotics (including fruit/berry polyphenol supplements) in the past 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cranberry beverageDaily consumption of 240 ml of cranberry beverage for 12 weeks. | Dietary supplement | Cranberry beverage |
| Placebo beverageDaily consumption of 240 ml of placebo beverage for 12 weeks. | Dietary supplement | Placebo beverage |
Primary outcome
Change in glucose homeostasis
Time frame: Pre and post each treatment (12 week/each)
Assessment of glucose concentrations during a 3-hour oral glucose tolerance test (OGTT)
Change in insulin secretion
Time frame: Pre and post each treatment (12 week/each)
Assessment of insulin a concentrations during a 3-hour oral glucose tolerance test (OGTT)
Change in insulin secretion
Time frame: Pre and post each treatment (12 week/each)
Assessment of C-Peptide concentrations during a 3-hour oral glucose tolerance test (OGTT)
Change in lipid profile
Time frame: Pre and post each treatment (12 week/each)
Assessment of triglycerides, LDL-cholesterol and HDL-cholesterol
9 secondary outcomes
Change in other measures of glucose homeostasis
Time frame: Pre and post each treatment (12 week/each)
Change in blood pressure
Time frame: Pre and post each treatment (12 week/each)
Change in chronic inflammation
Time frame: Pre and post each treatment (12 week/each)
Change in anthropometric measurements
Time frame: Pre and post each treatment (12 week/each)
Change in anthropometric measurements
Time frame: Pre and post each treatment (12 week/each)
Change in body composition
Time frame: Pre and post each treatment (12 week/each)
Change in gut microbiota
Time frame: Pre and post each treatment (12 week/each)
Change in gut microbiota function
Time frame: Pre and post each treatment (12 week/each)
Change in fat accumulation in the liver
Time frame: Pre and post each treatment (12 week/each)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2026.
Related trials for Overweight/Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cranberry beverage in people with Overweight/Obesity and Metabolic Syndrome, run by Laval University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julie Marois, M.Sc. (1-418-656-5258, julie.marois@fsaa.ulaval.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in glucose homeostasis (time frame: Pre and post each treatment (12 week/each)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2026.